+

WO1997045123A1 - Formulations pharmaceutiques topiques comprenant de l'aciclovir - Google Patents

Formulations pharmaceutiques topiques comprenant de l'aciclovir Download PDF

Info

Publication number
WO1997045123A1
WO1997045123A1 PCT/GB1997/001462 GB9701462W WO9745123A1 WO 1997045123 A1 WO1997045123 A1 WO 1997045123A1 GB 9701462 W GB9701462 W GB 9701462W WO 9745123 A1 WO9745123 A1 WO 9745123A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
aciclovir
water
topical pharmaceutical
pharmaceutical formulation
Prior art date
Application number
PCT/GB1997/001462
Other languages
English (en)
Inventor
Dean Selleseth
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to AU29698/97A priority Critical patent/AU2969897A/en
Publication of WO1997045123A1 publication Critical patent/WO1997045123A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • This invention relates to a topical pharmaceutical formulation suitable for use in treating virus infections of the skin and mucosa, and in particular it relates to topical formulations containing 9-(2-hydroxyethoxymethyl)guanine, otherwise known as aciciovir, and hereinafter referred to as such.
  • Aciclovir and pharmaceutically acceptable salts and esters thereof are known to have antiviral activity against various classes of DNA and RNA viruses both in vitro and in vivo, see UK patent No. 1 523 865.
  • the compound is active against herpes simplex virus which causes herpetic keratitis in rabbits, herpetic encephalitis in mice, and cutaneous herpes in guinea pigs.
  • Aciclovir has been found to be effective in the treatment of herpes simplex virus and herpes zoster virus in humans.
  • Aciclovir suffers from the disadvantage that it has a low solubility in water and is almost totally insoluble in hydrophobic solvent systems. It is accordingly difficult to produce a topical formulation containing a sufficient dissolved concentration of active ingredient for it to exert its full effect and also to optimise the flux of the compound into the skin. In addition to ease of release it is also important that any formulation of a pharmaceutically active compound should be stable for long periods of time, should not lose its potency, should not discolour or form insoluble substances or complexes, and also should not be unduly irritating to the skin or mucosa.
  • European Patent No. 0044 543 describes an oil-in-water topical pharmaceutical formulations of aciclovir wherein the aqueous phase contains at least 30% of a water miscible polyhydric alcohol,
  • oil-in-water topical pharmaceutical formulations of aciclovir comprising up to 5% w/w of a long chained polydispersed ⁇ -1 ,4- acetylated mannan have particularly advantageous properties.
  • such formulations exhibit enhanced efficacy together with low irritancy and good physical stability.
  • the present invention accordingly provides an oil-in-water topical pharmaceutical formulation comprising a dispersed oil phase and a continuous aqueous phase comprising water, solubilised aciclovir and up to 5% by weight of a long chained polydispersed ⁇ -1 ,4-acetylated mannan.
  • the long chained polydispersed ⁇ -1 ,4-acetylated mannan is a highly acetylated polydispersed linear mannan of molecular weight 1 - 2 million daltons.
  • the formulation of the invention contains a maximum of 50% water.
  • Such a topical formulation may contain 0.075% to 10% w/w aciclovir or a salt or an ester thereof, up to 5% w/w of a long chained polydispersed ⁇ -1 ,4- acetylated mannan, from 15% to 50% w/w water and an oil phase.
  • the composition will contain up to 1% of a long chained polydispersed ⁇ -1 ,4- acetylated mannan, most desirably between 0.1% and 0.6% w/w for example 0.3-0.5% w/w.
  • references to aciclovir should be understood to include also its pharmaceutically acceptable salts and esters unless the context clearly indicates otherwise.
  • the oil phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it is desirably comprised of a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, as explained in more detail below, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred
  • the emulsifier(s) with or without stabilisers make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so called emulsifying ointment base which forms the oil dispersed phase of the emulsions.
  • Emulgents and emulsion stabilisers suitable for use in the formulation of the present invention include cetyl alcohol, sodium lauryl sulphate, stearyl alcohol and polyoxyethylene alkyl ethers, such as polyoxyl stearyl ethers, for example steareth 2 and steareth 21.
  • the formulations of the invention may also comprise additional components in the aqueous phase, for example polyhydric alcohols such as propylene glycol or diethylene glycol monoethyl ether.
  • polyhydric alcohols such as propylene glycol or diethylene glycol monoethyl ether.
  • the formulations of the invention comprise from 0 to 40% by weight of propylene glycol.
  • the formulation comprises from 0.5% to 10% w/w aciclovir, up to 5% w/w of a long chained polydispersed ⁇ -1 ,4-acetylated mannan, from 20% to 40% w/w of diethylene glycol monoethyl ether, from 20% to 40% w/w water together with an oil phase, whilst the most preferred formulation comprises from 1% to 5% w/w aciclovir, up to 5% w/w of a long chained polydispersed ⁇ -1 ,4-acetylated mannan, from 30% to 40% w/w of diethylene glycol monoethyl ether, from 25% to 40% w/w water together with an oil phase.
  • Acemannan is the non-proprietary name of the biologically active component of C CAARRRRIISSYYNNTMTM aavvaaiillaabbllee ffrroomm CCaarrririnncgton Laboratories Inc., P O Box 168128, Irving, Texas, TX 75016-8128, U.S.A.
  • Diethylene glycol monoethyl ether is manufactured by Gattefosse S.A., 36 Chemin de Genas, b.p. 603, 69804 Saint-Priest Cedex, France, under the tradename TRANSCUTOLTM.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of aciclovir in most oils likely to be used in pharmaceutical emulsion formulations is very low.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dialkyl esters such as diisopropyl adipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a mixed ester of 2-ethyl hexanoic acid with a blend of cetyl or stearyl alcohols known as Crodamol CAP may be used, the last three being the preferred esters. These may be used singly or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
  • a preferred formulation according to the invention comprises, up to 5% w/w of a long chained polydispersed ⁇ -1 ,4-acetylated mannan, 30-40% w/w; aciclovir, approximately 5% w/w; cetyl alcohol 3-10% w/w; stearyl alcohol, 4-10% w/w; propylene glycol, 0-10% w/w; light mineral oil, 8-15% w/w; steareth 21 , 2-5% w/w; steareth 2, l-3% w/w; and purified water to 100% w/w.
  • the formulations of the invention may, if desired, include one or more pharmaceutically acceptable preservatives.
  • preservatives is not essential in the formulations of the invention, which finding represents an advantage of the said formulations.
  • the present invention also provides the use of aciclovir and a long chained polydispersed ⁇ -1 ,4-acetylated mannan in the preparation of a combined topical medicament for the treatment of herpes family viral infections.
  • a method of treating a viral infection caused by a member of the herpes family of viruses comprising topical administration of a pharmaceutically effective amount of a formulation according to the present invention.
  • the present invention further provides a method for the preparation of a topical pharmaceutical formulation, as hereinbefore defined, which comprises mixing the combination of aciclovir, long chained polydispersed ⁇ -1 ,4-acetylated mannan and water with the oil phase.
  • the manner of formulating the emulsion will of course vary according to the amount and nature of the constituents, but nevertheless follows known techniques in emulsion technology (see the Pharmaceutical Codex, London, the Pharmaceutical Press, 1979).
  • the aciclovir and long chained polydispersed ⁇ -1 ,4-acetylated mannan may be initially incorporated wholly in the aqueous portion where it may form a solution alone, or a mixed solution/suspension, and then emulsified with the ointment base.
  • a part of the aqueous portion may be formulated as an emulsion, and the balance of the water, long chained polydispersed ⁇ -1 ,4-acetylated mannan and aciclovir added to and dispersed into the emulsion.
  • the aciclovir may be included in the emulsifying ointment prior to emulsification with the aqueous portion. In using these procedures, it is preferable to heat the aqueous portion and the ointment base to about 40 to 80°C, preferably 50 to 70°C, prior to emulsification which may be achieved by vigorous agitation using for example a standard laboratory mixer. Finer dispersions of the oil phase may be obtained by homogenising or milling in a colloidal mill.
  • a topical formulation of the present invention may be used in the treatment or prevention of viral infections caused for example by Herpes zoster, Herpes varicella and Herpes simplex types I and 2, which cause diseases such as shingles, chicken pox, cold sores and genital herpes.
  • the formulation should desirably be applied to the affected area of skin from 1 to 6 times daily, preferably from 3 to 5 times.
  • Example 1 Ingredient % w/w
  • TRANSCUTOLTM 35 aciclovir 5.0 acemannan 5.0 stearyl alcohol 5.0 cetyl alcohol 4.0 light mineral oil 10.2
  • the oil phase comprising stearyl alcohol, cetyl alcohol, light mineral oil, brij 72 and brij 721 is heated to 70-75 °C with mixing.
  • Purified water is heated to 65- 70°C and added to the oil phase, maintaining the temperature at 70-75°C, with mixing to form an emulsion.
  • the mixture is maintained at a temperature of 70-75 °C for approximately 5 minutes.
  • TRANSCUTOLTM is weighed into an appropriate container and aciclovir added with mixing to form a suspension.
  • the aciclovir suspension is added to the emulsion, rinsing in with a small amount of purified water.
  • Acemannan is then added and the emulsion is homogenized for approximately 5 minutes, then made up to final batch weight with purified water.
  • the resulting cream is cooled to ambient temperature (approximately 30 °C) with continuous mixing and filled into suitable tubes which are then sealed.
  • TRANSCUTOLTM 27.5 aciclovir 5.0 acemannan 2.5 stearyl alcohol 5.0 cetyl alcohol 4.0 light mineral oil 10.2 brij 721 2.5 brij 72 2.3 propylene glycol 10.0
  • the oil phase comprising stearyl alcohol, cetyl alcohol, light mineral oil, brij 72 and brij 721 is heated to 70-75°C with mixing.
  • Purified water is heated to 70- 75°C and added to the oil phase, maintaining the temperature at 70-75°C, with mixing to form an emulsion.
  • the mixture is maintained at a temperature of 70-75 °C for approximately 5 minutes.
  • TRANSCUTOLTM is weighed into an appropriate container and propylene glycol and aciclovir added with mixing to form a suspension which is homogenized at 65-70 °C for approximately 5 minutes.
  • the propylene glycol aciclovir suspension is added to the emulsion at 50-70 °C, suitably 50-55 °C, rinsing in with a small amount of purified water.
  • Acemannan is then added and the emulsion is homogenised for approximately 5 minutes, then made up to final batch weight with purified water.
  • the resulting cream is cooled to ambient temperature (approximately 30°C) with continuous mixing and filled into suitable tubes which are then sealed.
  • the oil phase is weighed and heated to 70-75°C with continuous slow mixing.
  • Purified water is heated to 65-70°C.
  • the purified water is added to the aciclovir suspension with propeller agitation.
  • the aqueous mixture is heated to 65-70 °C. Whilst maintaining the temperature of the oil phase at 70-75 °C, the aqueous phase is slowly added with sweep agitation for at least 5 minutes.
  • the aqueous phase container is rinsed with purified water and the rinsings added to the main batch.
  • the temperature of the batch is maintained at 70-75 °C and the batch is homogenized for at least 5 minutes.
  • the batch is cooled to 30-35 °C with continuous sweep agitation and purified water added to adjust to final batch weight.
  • the batch is mixed until uniform and cooled to 30°C.
  • Example 4 5% aciclovir cream (marketed under the trademark ZOVIRAX ® by Glaxo Wellcome, Glaxo Wellcome House, Berkeley Avenue Greenford, Middlesex, UB6 ONN) consists of aciclovir solubilised in the aqueous phase of the oil-in- water cream base known as "MAC-P".
  • Poloxamer 407 (Pluronic F127 TM) 1.00
  • the water and propylene glycol are mixed at ambient temperature to produce an aqueous solution. If aciclovir is to be included in the formulation a part or all of it will be included in dissolved in this phase.
  • the parrafins and emulsifiers (cetostearyl alcohol, sodium lauryl sulphate) are mixed together and heated to 60 °C to form the oil phase which is then emulsified with the aqueous phase, also at using a laboratory mixer at 8000 r.p.m. Any remaining aciclovir is then added and the mixture dispersed and allowed to cool.
  • the ZOVIRAX ® (5% w/w aciclovir in MAC-P cream) formulation was compared with formulations containing both aciclovir and acemannan (made by mixing acemannan powder with the ZOVIRAX ® formulation) in the mouse snout model of herpes simplex virus (HSV) infection.
  • This mouse model involved infecting female HRS/J mice cutaneously with wild- type HSV-1.
  • Groups of ten mice were inoculated on the snout with a dilution of SC-16 HSV stock (1.1 E8 PFU/ml). After the mice were anesthetized with ketamine and xylazine, the skin on the snout region was lightly abraded with a roto-tool. The abrasion area was then swabbed for ten seconds with a sterile cotton swab soaked with the viral stock. Treatment was started three days post- inoculation (P.I.) and continued until day seven P.I. Mice were treated twice daily and scored for lesion severity daily.
  • Scoring system for the snout model is as follows:
  • Treatment groups were as follows (10 mice per group unless otherwise stated).
  • Example 4 The 0.1% w/w and 0.5% w/w acemannan plus 5% w/w aciclovir formulations of Example 4 were compared with 0.5% w/w and 1.0% w/w acemannan alone in the MAC-P cream base.
  • the cream base was made up as described in Example 4, with no aciclovir, and acemannan powder subsequently added.
  • the mouse model was as described in Example 4 except that treatment was continued for 8 days post infection. Again ZOVIRAX ® cream was the positive control.
  • Treatment groups were as follows (10 mice per group)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

On décrit une formulation pharmaceutique topique, huile-dans-eau, comprenant une phase huileuse dispersée et une phase aqueuse continue composée d'eau, d'aciclovir solubilisé et d'une quantité en poids pouvant aller jusqu'à 5 % d'un mannane β-1,4-acétylé, polydispersé et à longue chaîne.
PCT/GB1997/001462 1996-05-29 1997-05-29 Formulations pharmaceutiques topiques comprenant de l'aciclovir WO1997045123A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU29698/97A AU2969897A (en) 1996-05-29 1997-05-29 Topical pharmaceutical formulations comprising aciclovir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9611167.9A GB9611167D0 (en) 1996-05-29 1996-05-29 Medicaments
GB9611167.9 1996-05-29

Publications (1)

Publication Number Publication Date
WO1997045123A1 true WO1997045123A1 (fr) 1997-12-04

Family

ID=10794437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001462 WO1997045123A1 (fr) 1996-05-29 1997-05-29 Formulations pharmaceutiques topiques comprenant de l'aciclovir

Country Status (3)

Country Link
AU (1) AU2969897A (fr)
GB (1) GB9611167D0 (fr)
WO (1) WO1997045123A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158591C2 (ru) * 1998-03-30 2000-11-10 Уфимский научно-исследовательский институт глазных болезней Средство для лечения герпетических заболеваний глаз
US9775908B2 (en) 2007-07-10 2017-10-03 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Pharmaceutical preparations containing highly volatile silicones
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044543A1 (fr) * 1980-07-18 1982-01-27 The Wellcome Foundation Limited Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044543A1 (fr) * 1980-07-18 1982-01-27 The Wellcome Foundation Limited Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE CLERCQ, E.: "SELECTIVE VIRUS INHIBITORS", MICROBIOLOGICA, vol. 13, no. 2, April 1990 (1990-04-01), ITALY, pages 165 - 178, XP000575108 *
KAHLON J.B. ET AL.: "IN VITRO EVALUATION OF THE SYNERGISTIC ANTIVIRAL EFFECTS OF ACEMANNAN IN COMBINATION WITH AZIDOTHYMIDINE AND ACYCLOVIR", MOL.BIOTHER., vol. 3, no. 4, December 1991 (1991-12-01), USA, pages 214 - 223, XP002036152 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158591C2 (ru) * 1998-03-30 2000-11-10 Уфимский научно-исследовательский институт глазных болезней Средство для лечения герпетических заболеваний глаз
US9775908B2 (en) 2007-07-10 2017-10-03 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Pharmaceutical preparations containing highly volatile silicones
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Also Published As

Publication number Publication date
AU2969897A (en) 1998-01-05
GB9611167D0 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
EP0044543B1 (fr) Formulations topiques à base de 9(2-hydroxyéthoxyméthyl) guanine
US4963555A (en) Formulations of heterocyclic compounds
CZ285275B6 (cs) Topická farmaceutická kompozice
WO1997034607A1 (fr) Formulations d'aciclovir a usage local
WO1998010768A1 (fr) Compositions antivirales
WO1999012545A2 (fr) Medicaments contenant acyclovir
WO2009115510A1 (fr) Formulation antivirale
WO1997045123A1 (fr) Formulations pharmaceutiques topiques comprenant de l'aciclovir
EP1140117B1 (fr) Compositions d'acyclovir contenant du dimethicone
WO2017029298A1 (fr) Composition antivirale topique
AP197A (en) Pharmaceutical formulations for treatment of virus infections of the skin containing penciclovir.
EP0593562B1 (fr) Composition topique contenant du penciclovir
EP0416739A1 (fr) Compositions pharmaceutiques à base de penciclovir
KR100608963B1 (ko) 프로필렌 글리콜 및 이소프로필 알칸산 에스테르를포함하는 항바이러스 제제
US6469015B1 (en) Pharmaceutical formulation
US12280031B2 (en) Teriflunomide topical pharmaceutical compositions
MXPA01006490A (en) Aciclovir compositions containing dimethicone
JP2002302433A (ja) 低刺激性クリーム剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97541864

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载